HUMACYTE
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.
HUMACYTE
Industry:
Biotechnology Medical Medical Device
Founded:
2004-01-01
Address:
Morrisville, North Carolina, United States
Country:
United States
Website Url:
http://www.humacyte.com
Total Employee:
101+
Status:
Active
Contact:
9193139634
Total Funding:
692.86 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Global Site Tag
Current Advisors List
Board_member
2005-01-01
Board_member
2013-01-01
Current Employees Featured
Juliana L. Blum Co-Founder & Executive Vice President, Strategic Business Operations @ Humacyte
Co-Founder & Executive Vice President, Strategic Business Operations
2019-01-01
Laura E. Niklason Founder & CEO @ Humacyte
Founder & CEO
Shamik Parikh CMO @ Humacyte
CMO
2022-04-01
Dale A. Sander Chief Financial Officer and Chief Corporate Development Officer @ Humacyte
Chief Financial Officer and Chief Corporate Development Officer
2021-01-01
B.J. Scheessele Chief Commercial Officer @ Humacyte
Chief Commercial Officer
2021-08-01
Founder
Stock Details
Investors List
Fresenius Medical Care
Fresenius Medical Care investment in Post-IPO Equity - Humacyte
OrbiMed
OrbiMed investment in Post-IPO Equity - Humacyte
Alexandria Venture Investments
Alexandria Venture Investments investment in Post-IPO Equity - Humacyte
Morgan Creek Capital Management
Morgan Creek Capital Management investment in Post-IPO Equity - Humacyte
UBS O'Connor
UBS O'Connor investment in Post-IPO Equity - Humacyte
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - Humacyte
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Humacyte
Fresenius Medical Care
Fresenius Medical Care investment in Corporate Round - Humacyte
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Humacyte
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Venture Round - Humacyte
Key Employee Changes
Official Site Inspections
http://www.humacyte.com Semrush global rank: 4.77 M Semrush visits lastest month: 1.94 K
- Host name: ec2-67-202-46-212.compute-1.amazonaws.com
- IP address: 67.202.46.212
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Humacyte"
Leadership - Humacyte Global, Inc.
Jul 23, 2024 Dr. Niklason is the founder of Humacyte and has served as its President and CEO since 2020. She served Humacyte as a senior scientist from 2004 through 2020. ... Mr. …See details»
Humacyte - Crunchbase Company Profile & Funding
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery …See details»
Our Story - Humacyte Global, Inc.
Jul 23, 2024 Our commitment to disruptive, meaningful innovation goes beyond mere advancement. It’s a dedication to setting new standards that challenge the status quo and …See details»
Humacyte - The Org
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients …See details»
Humacyte, Inc. Announces Proposed Public Offering of Common …
2 hours ago DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally …See details»
Org Chart Humacyte - The Official Board
Organizational Chart of Humacyte. Humacyte www.humacyte.com. has 21 executives +1 919 313 9633; Add an executive. Humacyte (HUMA) News . Anything missing? We search for you. …See details»
Investor Relations - Humacyte, Inc.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ …See details»
Humacyte, Inc. Announces Proposed Public Offering of Common
2 hours ago Humacyte Investor Contact: Joyce Allaire LifeSci Advisors LLC +1-617-435-6602 jallaire@lifesciadvisors.com investors@humacyte.com. Humacyte Media Contact: Rich …See details»
Humacyte - Funding, Financials, Valuation & Investors - Crunchbase
Humacyte is registered under the ticker NASDAQ:HUMA . Humacyte is funded by 15 investors. Fresenius Medical Care and OrbiMed are the most recent investors. Humacyte has a post …See details»
Annual Reports - Humacyte, Inc.
Mar 29, 2022 The Investor Relations website contains information about Humacyte, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Humacyte, Inc. (HUMAW) Company Profile & Overview
Mar 10, 2025 Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions …See details»
Humacyte - Contacts, Employees, Board Members, Advisors
Humacyte develops products for vascular diseases and replacement of anatomical conduits. New. Resources. Advanced Search ... Experience the new Crunchbase, powered by AI . Experience …See details»
Humacyte Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Humacyte is a regenerative medical technology company focused on the development of human acellular matrix products for vascular and non-vascular applications. It …See details»
Humacyte, Inc. (HUMA) Company Profile & Facts - Yahoo Finance
See the company profile for Humacyte, Inc. (HUMA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Humacyte - Overview, News & Similar companies | ZoomInfo.com
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024 DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: …See details»
Bioengineering Process - Humacyte Global, Inc.
Our first-in-class bioengineering technology and manufacturing process aims to transform human cells into universally implantable, regenerative tissues and advanced organ systems, for use in …See details»
Humacyte, Inc. - AnnualReports.com
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the …See details»
A Deep Dive Into Humacyte Inc: Pioneering Bioengineered Human …
Dec 23, 2024 Humacyte Inc was founded in 2004 by Dr. Laura Niklason, a Yale professor and one of the world’s leading experts in vascular and tissue engineering. Her groundbreaking …See details»
Humacyte down 13% amid reports that FDA approved device …
3 hours ago A former U.S. FDA employee said he and other agency reviewers were pressured to approve Humacyte's (NASDAQ:HUMA) Symvess, an artificial blood vessel, despite safety …See details»
Support & Resources - Humacyte Global, Inc.
Humacyte® is dedicated to delivering exceptional value to clinicians across various therapeutic areas and healthcare settings, all with a focus on prioritizing patient care. Our extensive …See details»